Abstract B-cell lymphomas encompass a large number of disease entities clinically ranging from indolent to aggressive. The defining pathological features usually predict clinical course, with small and large B-cell lymphomas correlating to lowgrade vs high-grade features, but discordant situations may be encountered. Two sessions of the workshop of the XVIII meeting of the European Association for Haematopathology (EAHP) held in Basel in 2016 addressed this topic. One session illustrated various facets of Baggressiveness^in indolent lymphomas, either peculiar clinical manifestations, cytological variants, or unusual genetic features, as well as several examples of progression or transformation to a more aggressive disease. Another session exemplified large B-cell lymphomas with unexpected indolent behavior including cases arising in welldefined body compartments or in sanctuary sites. This paper describes the features of the cases presented in both groups, highlights the most salient points of discussion raised by the submitters and the panel, and summarizes current knowledge and recommendations relevant to diagnostic pathology practice.
Introduction
Indolent lymphoma is defined as a lymphoma which tends to grow and spread slowly and has few symptoms usually not requiring immediate chemotherapeutic intervention (Blowgrade^). Conversely, aggressive lymphomas are associated with a rapid growth and progressive clinical course (Bhighgrade^). These definitions, based on clinical presentation, clinical course, and biological features, correspond to two broad categories of diseases and pathological entities [1] .
Indolent lymphoma equates to small B-cell lymphoma entities, the most frequent and prototype being follicular lymphoma, followed by small lymphocytic lymphoma/chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, marginal zone lymphoma (of extranodal, nodal, and splenic types), and hairy cell leukemia [2] . Mantle cell lymphoma, although Laurence de Leval and Christiane Copie-Bergman contributed equally to this work.
This article is part of the Topical Collection on Aggressive B-cell lymphomas and histiocytic neoplasias composed usually of small B cells, is typically characterized by an aggressive behavior. Despite slow disease evolution and treatment responsiveness, indolent lymphomas essentially represent incurable chronic diseases. They may pose clinical issues due to the tumor mass, or a more rapidly evolving disease with treatment resistance in some instances, and there is a cumulative risk of transformation to a high-grade lymphoma [1, 3] .
Diffuse large B-cell lymphomas represent the prototype of aggressive B-cell lymphomas, which in principle require immediate treatment often with poly-chemotherapy associated with an immunological agent, resulting in long-term remission/cure in more than 50% of the patients. However, there is a group of lymphomas that have high-grade morphological features and indolent clinical behavior, which typically arise in well-defined body compartments or in sanctuary sites.
This paper summarizes two sessions of the workshop of the XVIII meeting of the European Association for Haematopathology (EAHP) held in Basel in 2016. These sessions of the workshop were dedicated to B-cell lymphomas with discordance between pathological features and clinical behavior. One session comprised 47 cases illustrating various facets of Baggressiveness^in indolent lymphomas, either peculiar clinical manifestations, cytologic variants, or unusual genetic features, as well as several examples of progression or transformation to a more aggressive disease. The other session comprised 13 cases exemplifying large B-cell lymphomas with unexpected indolent behavior.
Indolent lymphomas with aggressive features Follicular lymphomas
Follicular lymphoma (FL) is one of the most common nonHodgkin lymphomas (NHLs) in Western countries accounting for 20-30% of adult lymphomas and 70% of indolent NHLs [1] . FL typically exhibits a follicular growth pattern and is composed of centrocytes admixed with a variable proportion of centroblasts. The cells have a CD20+ CD5− CD10+, BCL6+, and BCL2+ immunophenotype, and 80-90% carry the t(14;18)(q32;q21) IGH-BCL2 translocation. Progression of FL usually refers to transition from grade ½ to 3A or evolution to a more diffuse growth pattern, while transformation is defined by a diffuse high-grade B-cell lymphoma. In addition, FL may display a variety of features suggestive of more aggressive behavior.
Follicular lymphoma with double/triple-hit MYC/BCL2/BCL6
Four cases of de novo FL with double-hit (DH) BCL2/MYC (#321, P. Mroz) or triple-hit (TH) BCL2/BCL6/MYC (#102, G. Caponetti; #386, D. Weisenburger; #171, P. Farinha) rearrangements were reviewed by the panel. In contrast to these aggressive cytogenetic features, all of them were de novo nontransformed FL, grade 1/2 (n = 3) or grade 3A (n = 1), with classical CD20+, CD3−, CD10+, BCL6+, and BCL2+ immunophenotype. MYC protein expression was less than 10% in two cases and expressed in 80% of the tumor cells in the other two cases, and the proliferative index (PI) evaluated by Ki67 immunostaining ranged from 10 to 80%. The MYC partner gene could be investigated in three of four cases and was of non-IG subtype (including the CD96 gene) in the two cases with <10% MYC protein-positive tumor cells, and IGH in one case with high MYC expression. One patient had localized disease but three patients presented with asymptomatic stage IV disease, including one patient with exclusively skeletal disease and multiple bone lesions who remained untreated for 1 year before being lost to follow-up (#102). Interestingly, one patient with TH FL relapsed at 9 years with a FL 1/2 carrying an isolated BCL2 break and experienced complete remission without therapy (#171). None of the three patients with available follow-up had an aggressive clinical course.
MYC translocation in de novo non-transformed FL 1-2/3A is a rare event. Six cases of FL with MYC rearrangement and germline BCL2 gene have been described with a follicular and diffuse architecture, grade 1 to 3 morphology, and an indolent behavior [4] . Less than 20 well-documented cases of FL 1/2 with double-hit MYC/BCL2 have been published including a recent series of seven patients (median age 47 years with a male predominance) with stage IV nodal and extranodal disease [5] . The DH FL were grade 1-2 to 3A with a follicular growth pattern, without any blastoid morphological features, classical immunophenotype, MYC protein expression <30%, and Ki67 ranging from 5 to 50%. Three patients treated with standard regimen for FL had a poor outcome, and four patients treated with a more intensive regimen for DH lymphoma achieved complete remission. In total, DH/TH de novo FL patients' prognosis remains unpredictable with either unexpectedly good outcome as in the cases submitted to the workshop, or more aggressive behavior as recently reported [5] .
FL with high proliferative index
Two cases of FL with high Ki67 PI were submitted: one extranodal BCL2-negative (with clones 124 and E17 antibodies) FL 1/2 without detectable BCL2 and BCL6 breaks with bilateral breast involvement in a 82-year-old man (#256, W. Xue) and one disseminated FL 1/2 with a classical immunophenotype, t(14;18) positive in a 66-year-old man (#318, N. Panesar). The latter case displayed follicles with a starry-sky appearance, a proliferative index of 100%, and was extensively documented by array-CGH analysis showing gains of 7q31 and losses at 1p36 and 9p24 (CDKN2A, CDKN2B). The patient responded well to 6 cycles of Rbendamustine followed by rituximab maintenance therapy.
Ki67 index correlates in general with the FL grade but a high Ki67 level (30 to 40% or more) is observed in up to 20% of FL 1/2. As recommended in the report of the Istanbul EAHP meeting, the WHO grading should be retained for such cases with an additional comment that FL 1/2 with high PI might pursue a more aggressive course [6] . Delineation of these forms from FL with blastoid features is also important. Currently, the prognostic significance remains controversial. Blastoid features refer to cytological features reminiscent of precursor cells, i.e., medium-sized cells with finely distributed chromatin and occasional presence of small nucleoli, resembling lymphoblasts or small centroblasts. As emphasized in the past [7] , there is poor reproducibility in recognition of this variant, and accordingly, several cases submitted to the workshop where either not recognized as blastoid by the submitter and designated as such by the panel or vice-versa. When blastoid features are encountered, the first step is to rule out transformation to a high-grade lymphoma or lymphoblastic lymphoma (by performing TdT staining); in the context of follicular lymphoma, the term Bfollicular lymphoma not gradable with blastoid features^is recommended [7] .
FL with BCL2 or NOTCH gene mutations FL may be associated with different mutational profiles with variable prognostic significance. Three cases were submitted with acquired BCL2 or NOTCH mutations or with inherited TP53 mutation in the context of Li Fraumeni syndrome for one case. One case of BCL2-mutated FL grade 1/2 (#112, RL. King) occurred in a 42-year-old male, who presented with pancytopenia, extensive lymphadenopathy, and died after 6 years following six different lines of therapy including autologous cell transplant. BCL2 coding sequence mutations are reported to occur in 12% of FL 1/2 at diagnosis using Sanger sequencing. Mutations in the region of BCL2 coding for the epitope recognized by the common anti-BCL2 antibody may cause false negative immunohistochemistry results, and alternative antibodies recognizing other epitopes may be necessary to demonstrate BCL2 expression in these cases [8, 9] . FL with BCL2 mutations have been associated with increased risk of transformation and shortened survival in a retrospective series of de novo FL treated in the pre-rituximab era [10] . However, more sensitive deep DNA sequencing methods have shown up to 76% BCL2 mutation rates in FL [11] , and further studies are warranted to confirm the prognostic value of BCL2 mutations in FL patients treated with rituximab-containing chemotherapy.
One case highlighted the peculiar features of NOTCH-mutated FL (#266, F. Sen). In this 43-year-old woman, a cervical lymph node biopsy was first performed showing a NOTCH1-mutated B-cell lymphoma with a marginal zone pattern and increased large cells. Splenectomy performed a few months later displayed a CD10−, BCL2−, t(14;18) negative FL 1/2 with a high proliferative index (Fig. 1) . Although the relationship between the two diseases was difficult to assess on morphological grounds, additional studies performed by the panel showed that they were clonally related. NOTCH mutations that occur in about 6% of FLs are associated with a female predominance, lower frequency of t(14;18), higher incidence of spleen involvement, and a significant association with DLBCL [12] . NOTCH mutations do not seem to have a prognostic impact in FL, but additional studies on larger series are needed.
Transformed FL
Eleven cases of transformed FL (tFL) were submitted to the workshop. FL transformation into more aggressive lymphoma is observed in 2 to 3% of patients per year [7, 13] . FL transforms into different histologic subtypes, including DLBCL, B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (formerly BCLu) or with blastoid morphology (TdT-negative), and lymphoblastic type (TdT-positive) lymphoma. According to the WHO 2016 update, the former BCLu cases are now distributed into two new categories: high-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 translocations (for those carrying double-hit = DH or triple-hit = TH) and HGBL-not otherwise specified (NOS) for the others [14] . The morphologic subtype (DLBCL vs BCLu vs blastoid vs lymphoblastic) and the statement Btransformed from FL^should be added in the pathology report (example, HGBL, with BCL2 and MYC rearrangement, DLBCL morphology, transformed from FL^). It is recommended to demonstrate the clonal relationship between the two components. Importantly, HGBL-DH should be restricted to mature aggressive lymphomas and therefore excludes FL and lymphoblastic lymphomas with DH/TH. The 11 tFL submitted to the workshop included 2 DLBCL associated with FL and 9 HGBL-DH/TH with DLBCL (n = 7), BCLu (n = 1), or blastoid morphology (n = 1) (#263, R. Felgar) (Fig. 2) . In most HGBL, FL and HGBL components were diagnosed simultaneously at different sites, with FL in nodal or extranodal (lung, spleen, salivary gland) locations and HGBL in the bone marrow (BM) being the most frequent scenario, highlighting the importance of staging bone marrow biopsy. Only two cases had HGBL nodal involvement with concurrent FL in the bone marrow. One case with FL 1/2 in the spleen had BM and leukemic dissemination of the HGBL (#280, SS. Chuang).
Interestingly, in two cases, the tFL was EBV-associated. Acquisition of EBV during transformation is overall a rare event and might be confused with the probably more frequent reactivation of intra-and peritumoral EBV in non-neoplastic Regarding the molecular subtypes of tFL, nine were germinal center-like (GC) and the two EBV-associated tFL were non-germinal center-like (NGC) according to Hans algorithm [15] . This is consistent with the literature where tFL have been reported as germinal center (GC), activated B cell type (ABC), or unclassified in 80, 16, and 4%, respectively, using transcriptomic analysis [13] . Four out of six patients with clinical follow-up died, one had progressive disease, and one achieved complete remission (case 295, 7-month follow-up).
Lymphoplasmacytic lymphoma
Lymphoplasmacytic lymphoma (LPL) is a neoplasm of small lymphocytes, plasmacytoid, lymphocytes, and plasma cells, usually involving the bone marrow and sometimes lymph nodes and spleen, which does not fulfill the criteria for other small B-cell lymphomas that may have plasmacytic differentiation (Fig. 3a, c) [16] . The majority of LPL patients have Waldenström's macroglobulinemia (WM) (defined as bone marrow involvement by LPL and a IgM serum paraprotein of any concentration), but this feature is not mandatory for LPL diagnosis [16] . More than 90% of LPL have MYD88 L265P mutation, but this abnormality is not specific as it is also encountered in other small B-cell lymphomas and a subset of DLBCLs [17] . About 30% of the patients harbor somatic mutations in CXCR4 (most commonly the nonsense truncating S338X or frameshift mutations in the C-terminal domain) in addition to the activating MYD88 L265P mutation, and this genotype tends to correlate with higher disease activity [18] . The uncommon cases with wild-type MYD88 and those with CXCR4 mutations have reduced responsiveness to Bruton's tyrosine kinase inhibitor ibrutinib [18] [19] [20] .
The Bing-Neel syndrome designates a very rare manifestation of WM with neurological symptoms due to infiltration of the central nervous system by lymphoplasmocytoid cells or due to humoral factors in the absence of cellular infiltrate of the brain or cerebrospinal fluid [21, 22] . Case #202 submitted by L. Venkatraman illustrated an example of this complication in a patient who presented with depression, headache, and visual symptoms 4 years after a diagnosis LPL/WM. Imaging abnormalities were detected by MRI, but no abnormal cellular infiltrate was definitively demonstrated. BingNeel syndrome by definition excludes cases of transformation to high-grade lymphoma, but this patient later developed transformation to DLBCL involving the lacrimal gland and the brain.
Transformation of LPL to DLBCL occurs rarely (cumulative incidence <5% at 15 years) and is associated with a bad outcome [23, 24] . Development of Hodgkin lymphoma has been reported rarely in LPL patients [25] . Five cases of transformed LPL were submitted to the workshop (#171, M. Buehler; #238, L. Venkatraman; #202, C. DommannScherrer; #332, T.N. Aladily; #252, H. Van Krieken). The patients had a 5-to 15-year history of LPL and four had WM. Among four cases tested for mutations, all were positive for MYD88 L265P, three were wild-type for CXCR4, and one had a CXCR4 frameshift mutation. Transformation was observed in lymph nodes in three patients and in extranodal sites in two. Histology at transformation was DLBCL in four cases including a case of plasmablastic lymphoma (Fig. 3a, b) , and there was an exceptional case of clonally related EBV-positive lymphoproliferation with Hodgkin-like features in one patient who had undergone stem cell transplantation for disseminated LPL (#252) (Fig. 3c-f) . MYC rearrangement was documented in two DLBCL cases at transformation. Three of the patients with transformation to DLBCL died of disease, sometimes after prolonged evolution, but one patient is alive with disease persistent in the form of low-grade LPL 1 year after transformation and chemotherapy.
LPL may include an increased proportion of large cells, and there are no precise guidelines as to the threshold to consider transformation to DLBCL. Two cases were submitted (#317, D. Gur and #364, E. Mason) that were considered by the panel to represent LPL enriched in large cells. Both patients had massive bone marrow involvement, comprising an admixture of small and larger blastic cells. The latter, however, did not form confluent sheets, and based on this, it was felt that the diagnosis of DLBCL was not warranted. One of those patients had a long history of LPL with multiple lines of therapy, and MYD88 mutated/CXCR4 wild-type genotype together with an ARID1 mutation (Fig. 3g-h) . A biopsy in a second patient was obtained 3 months after initial diagnosis, and after worsening of anemia, a peculiar feature in this case was the demonstration of an as yet unreported genotype (MYD88 wild-type/CXCR4 frameshift mutation).
B-cell leukemias
Small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL) is an indolent neoplasm of small mature CD5+ CD23+ B cells, with a small proportion of prolymphocytes distributed within proliferation centers seen in tissue sections [16] . Clinical progression has been associated with histologically aggressive forms, characterized by expanded proliferation centers or increased proliferation fraction (Ki67 > 40%) [26, 27] or an increased proportion of prolymphocytes (>10%) in the peripheral blood [28] .
Transformation of CLL into an aggressive disease may result from prolymphocytoid transformation (defined by more than 55% prolymphocytes in the peripheral blood) or Richter's syndrome [16] . The two cases of prolymphocytoid transformation of CLL (#59, D. Grier and #170, B. Rea and A. Bagg) occurred at 10 and 13 years after CLL diagnosis and exhibited both typical peripheral blood morphologies. In case #170 (Fig. 4a) , the karyotype obtained at transformation contained a t(8;14)(q24;q32) translocation, but neither MYC nor IGH was involved in the rearrangement, which was retrospectively found to be already present at CLL diagnosis. Interestingly, a number of candidate oncogenes map to these loci (ZHXQ @ 8q24 and TCL1 @ 14q32) and are possibly deregulated by the rearrangement.
Richter's syndrome (RS) is a term used to designate a clinical situation characterized by the sudden transformation into an aggressive disease in a patient with CLL/SLL, which occurs in 5-10% of the cases [29] [30] [31] . Histologically, most cases are represented by DLBCLs but there is also a Hodgkin variant of RS accounting for a minority of the cases [32] . Although RS and BRichter transformation^seem to be used interchangeably in the literature, and most RS represent clonal evolution of the preexisting SLL/CLL, there is a subset of the cases that are clonally unrelated to the CLL and represent secondary malignancies. The latter includes a small proportion of DLBCLs and the majority of Hodgkin-type cases [33, 34] . Interestingly, the two RS subsets defined by clonal relationship are associated to distinct molecular features with a higher proportion of TP53 alterations found in clonally related cases. There are different prognoses with clonally unrelated Fig. 3 RS being associated to a significantly longer survival compared to clonally related RS who do very poorly [35] . Given the clinical impact of clonal relationship of the RS to the CLL, the panel recommended investigation of this feature in every case when possible and to restrict the use of the term Btransformation^to cases that represent clonally related lesions only. The definitive answer ultimately relies on molecular tests to compare the sequence of VDJ gene rearrangements or the genomic profiles of both lymphoproliferations.
One of the cases of RS (#273, M. Sharifian) was a classical example of a transformation to a DLBCL clonally related to the preexisting CLL, and associated to acquisition of MYC rearrangement, that occurred only 2 years after CLL diagnosis. The RS presented by D. Weisenburger (#384) occurred in a patient with SLL and no significant lymphocytosis, and consisted of EBV-negative MYC-rearranged plasmablastic lymphoma clonally unrelated to the preexisting SLL. There was a complex case of a composite lymphoma presented by A. Perry (#348) (Fig. 4b-d) ; the initial lymph node in that patient comprised FL associated with an interfollicular involvement by SLL, plus foci of cyclinD1-positive in situ mantle cell neoplasia, harboring a CCND1 rearrangement confirmed by FISH. Interestingly, although both the FL and SLL had distinct immunophenotypes, a PCR analysis for IGH gene rearrangement demonstrated only a single band, and both components harbored a BCL2-IGH fusion. The patient's disease later evolved towards a lymphoma with the features of classical Hodgkin lymphoma, EBV-negative, and the panel was able to demonstrate the presence of BCL2-IGH fusion in the Reed-Sternberg cells. That represents an exceptional example of clonally related Hodgkin lymphoma complicating a composite lymphoma including t(14;18)-positive SLL.
B cell prolymphocytic leukemia (B-PLL) is a neoplasm of B prolymphocytes affecting the peripheral blood, bone marrow, and spleen, with prolymphocytes exceeding 55% of lymphoid cells in the peripheral blood [16] . Cases of CLL with increased prolymphocytes or prolymphocytoid transformation as well as lymphoproliferations associated to a t(11;14) translocation fusing IGH and CCND1 are by definition excluded [36] . Numerical or structural abnormalities of the MYC gene have been reported in B-PLL [37] , and were indeed present in the three cases submitted to the workshop. One case (#305, E. Hsi) (Fig. 4e-g ) with a complex karyotype including a t(8;14)(q24.1;q32) was characterized by a relatively low absolute lymphocytosis and a long indolent clinical course, prior to transformation to a clonally related plasmablastic lymphoma. Case (#302, X. Wu) with an extra MYC copy showed that a typical prolymphocytic morphology in the blood and bone marrow (Fig. 4h) had spleen involvement and a dismal prognosis.
An exceptional case of hairy cell leukemia presented by M. Piris (#169) showed massive splenic involvement by large blastic cells, while scattered smaller cells with a morphology of hairy cells were observed in the peripheral blood [38] . A BRAF mutation was demonstrated together with triple-hit involving BCL2, BCL6, and MYC rearrangements. This situation generated discussions regarding the most appropriate classification of this case, as a high-grade B-cell lymphoma with triple hit vs blastoid hairy cell leukemia. The latter designation was favored given that the peculiar clinical and pathological features of hairy cell leukemia were clearly present; that patient expired shortly after diagnosis.
Mantle cell lymphoma
Mantle cell lymphoma (MCL) is usually characterized by an aggressive behavior; however, subsets of MCL with an indolent behavior recognized over the past years, namely, in situ mantle cell neoplasia and non-nodal leukemic MCL, are now individualized in the revised WHO classification [14, 39, 40] . Leukemic non-nodal MCL is usually positive for cyclin D1, carries the t(11;14) translocation, but tends to be negative for SOX11 [14, 39] . Despite a usually indolent clinical course, these cases may transform and one example was illustrated by case #133 (L. Soma and S. Chen) (Fig. 5) . The patient presented with a leukemic picture comprising two components, one of small CD5-positive cells and the other of larger blasts with cells carrying a MYC rearrangement. Two other cases were presented that illustrated situations where leukemic MCL could be confused with CLL. In one case, there was absence of cyclin D1 expression despite IGH-CCND1 rearrangement, in the other one due to absence of demonstrable CCND1 rearrangement, that turned out to be cryptic on standard karyotype and not identified by FISH; in the latter case, the clinical evolution was aggressive and the patient died of disease at 8 months (#142, J. Cook).
Case #352 (E. Sabattini) exemplified a peculiar nodal MCL with mixed small cells and pleomorphic components, the latter showing a marginal zone pattern with IRTA-1 expression, SOX11 positivity, and no detectable cyclin D1 expression despite the presence of a CCND1 gene rearrangement evidenced by FISH. Similar cases of cyclin D1-protein-negative, t(11;14)-positive MCL have been previously reported and so far that phenomenon remains unexplained [40] .
Aggressive lymphomas with indolent clinical behavior
Large B-cell lymphoma associated with thrombus, myxoma, or prosthesis in the heart Primary cardiac lymphoma (PCL) is a rare disorder accounting for 1% of cardiac tumors and only 0.5% of extranodal lymphomas [42] . There have been reports of lymphomas that arise within the cardiac chambers with a particularly indolent course [43, 44] . Similar cases have been reported in association with cardiac prostheses, vascular grafts, and around joint prostheses [45, 46] . In the heart, the right side is involved more frequently than the left [44] and the lymphomas are often associated with atrial myxoma or prosthetic valves [43, 46] . PCL involving native heart valves is very uncommon [43, 47] .
Two cases in the workshop illustrated the unique features of PCL (#117, A. Joshi; #337, A. Ruano). One case arose within a cardiac thrombus (#337) (Fig. 6) , while the other was associated with thrombus attached to a bioprosthetic mitral valve [37] . The clinical presentation in both cases was rather non-specific including shortness of breath and pulmonary edema. This presentation is quite typical of PCL where the presentation is characteristically associated with effusions, constitutional symptoms, and/or shortness of breath.
Morphologically, the cells in PCL are reported to be large and embedded in fibrin or thrombus without invasion of the m y o c a r d i u m . T h e c e l l s h a v e a t y p i c a l B c e l l immunophenotype and are generally non-germinal center type. They are usually positive for EBV with a type III latency pattern [43, 47] . Both submitted cases showed clonal IGH gene rearrangement.
These two cases illustrate the indolent clinical course with one patient alive and disease free without any further treatment. The cases in the literature also show a favorable outcome, and recognition of these PCLs is important to avoid potential overtreatment.
The pathogenesis of these lymphomas and the explanation for their unusually indolent behavior remains unclear. Most cases arise in immunocompetent patients, but it has been suggested that there may be localized reduction of immune surveillance confined to the location in which the lymphoma develops [43, 48] . This may be due to increased local concentrations of IL-6 as a result of local inflammatory response, increased concentration of IL-10 locally, or by the sequestration of the neoplastic cells within clot that is not well penetrated by normal immune regulatory cells [43] . PCLs are more often encountered in older aged patients, and age-related immune senescence should also be considered as a potential contributory factor [43] . These are very rare lymphomas, but from the cases presented in the literature, it can be postulated that complete resection of the thrombus and/or prosthesis may be curative avoiding the requirement for more aggressive poly-chemotherapy.
Effusion lymphoma associated with fluid overload
Primary effusion lymphoma (PEL) is a rare B-cell lymphoma that is confined to body cavities associated with pleural, pericardial serous effusions or with peritoneal ascites. Typically, PEL is a human herpes virus 8 (HHV8)-related lymphoma encountered in the context of human immunodeficiency virus (HIV) infection that has a very poor outlook with median survival of 3-4 months. It is characterized by a proliferation of large-cell morphologically intermediate between immunoblastic and anaplastic large cells. The cells tend to lack pan-B cell antigens such as CD19, CD20, and CD79a while retaining expression of CD45 with positive staining for plasma cell and activation markers (CD38, CD138, and CD30). They show positive nuclear staining for HHV8-associated latent protein LANA and are negative for EBV.
Cavity-based B-cell lymphomas unrelated to HHV8 infection (HHV8-unrelated, PEL-like lymphomas) may occur in other clinical scenarios [49, 50] . These may be divided into effusion-based Burkitt lymphoma (with MYC rearrangement, EBV-positive or negative) and effusion-based large B-cell lymphomas characterized by large-cell morphology, absence of MYC rearrangement but possibility of MYC amplification, and variable EBV status. In contrast to classical PEL, the cells retain expression of pan-B cell markers while markers of plasma cell differentiation and activation are usually negative. The patients are usually older and the outlook is significantly superior to classical PEL with a median survival up to 10 months, while a 35% 1-year survival has been reported.
HHV8-unrelated PEL-like lymphoma was illustrated by one case (#313, M.F. van den Hout). The patient was an elderly (85 yrs) male with massive pericardial effusion but without significant previous medical history and tested negative for HIV. The pericardial effusion was drained and microscopic examination revealed a population of large cells, many with immunoblastic morphology. The cells stained for CD20 and CD79a while they were negative for CD138, CD30, HHV8, and EBER. Due to the advanced age of the patient and the lack of other symptoms or evidence of disseminated disease, no further intervention was undertaken and the patient was alive and apparently disease free 3 months later.
This case highlighted many of the features that distinguish classical PEL from PEL-like lymphoma. PEL-like lymphoma typically presents at an older age and is usually associated with disorders that are associated with serous effusions such as heart failure or cirrhosis [41, 50] . The aetio-pathogenesis of the lymphoma is unclear but is unrelated to HIVor HHV8 [41, 50] . There has been a reported association with hepatitis C virus [49, 51] , and a proportion may be related to EBV [50, 52] . Due to the rarity of these lymphomas, the optimal therapy is unclear. Many patients may be unsuitable for aggressive therapy, but where appropriate, poly-chemotherapy may be used in combination with anti-CD20 immunotherapy [50, 51] . It has been suggested that many cases may be undiagnosed as the effusion may be dismissed as being related to heart failure, and there are cases, such as the one submitted to the workshop, that have received no active therapy and have regressed following fluid drainage with or without pleurodesis [51] . A useful diagnostic test may be fluid to serum LDH ratio which has been reported to be very high in these cases [51] .
Large B-cell lymphoma confined to peripheral nerve Neurolymphomatosis (NL) designates the presence of infiltration of nerve trunks, nerve roots, and plexi and cranial nerves by lymphoma cells [53] . NL is rare and may occur as part of disseminated lymphoma, but less commonly, the lymphomatous infiltrate is confined to a peripheral nerve (primary lymphoma of peripheral nerve (PLPN)) [54] with a high proportion of the cases described in the literature involving the sciatic nerve [55] . Almost all of the cases of PLPN have been DLBCL [56] . The age of presentation is usually 34-72 years (mean 57.3 years) with a higher incidence in men [56] . Deletion of the CDKN2A/p16 gene has been described in some cases and may be a negative prognostic factor [57, 58] . A pre-existing history of auto-immune disease has been suggested as a predisposing factor [57, 58] . Possible explanations for location in peripheral nerve may include the presence of B cells within the peripheral nerve [59] or the expression of specific adhesion molecules [60] .
A single case of PLPN was submitted to the workshop (#350, S. Dojcinov). The patient presented with pain in the left upper forearm and hand consistent with carpal tunnel syndrome. Decompression was performed but the symptoms progressed with flail arm and muscle wasting. Subsequent imaging studies revealed thickening of the brachial plexus with increased PET activity confined to the brachial plexus and median nerve. A nerve biopsy revealed DLBCL with expressions of CD20, BCL6, BCL2, and MUM1, while the cells were negative for CD10, CD5, CD23, CD43, and EBER.
The case illustrated many of the typical features seen in PLPN. Reaching the correct diagnosis is often difficult and usually requires nerve biopsy or large resection. In some cases, the lesion may be mass-forming and misdiagnosed as schwannoma [61] . Most cases are treated as usual DLBCLs [53, 55, 57] . The case submitted to the workshop was treated with 6 cycles of R-CHOP chemotherapy with intra-thecal prophylaxis to complete response but relapsed 24 months later with contralateral brachial plexus involvement that was treated with intensified chemotherapy and autologous stem cell transplant resulting in remission that has extended so far for a further 12 months. This clinical behavior is in contrast to many of the cases reported in the literature where the clinical outlook for NL is generally poor with median survival of around 10 months [53] . There are frequent relapses in the central nervous system. However, there is possibly a better prognosis for primary compared to secondary NL [53] .
Conclusions
Some cases of indolent lymphomas encompass a spectrum of morphological, immunophenotypical, and genetic/molecular features that might suggest a potentially more aggressive behavior. All features must be interpreted in the light of the morphology and clinical context. In particular, MYC rearrangement may be observed in de novo low-grade B-cell lymphomas, in the absence of histological transformation; such a finding should be mentioned in the diagnostic report but is not necessarily indicative of an increased risk of clinical progression.
Transformation of indolent to aggressive B-cell lymphomas comprises a cytological spectrum including large-cell, blastoid, Burkitt-like, prolymphocytoid, or even Hodgkinlike proliferations. In follicular lymphomas, DLBCL not otherwise specified and high-grade B-cell lymphoma double-hit represent the most common forms of transformation. The basis for considering histological transformation is the identification of sheets of large transformed cells. There remains a category of Bintermediate^cases with an increased number of large cells not considered sufficient to warrant a diagnosis of transformation that are difficult to interpret. Although the high-grade transformation is usually clonally related to the preexisting small B-cell lymphoma, a subset of the cases represent clonally unrelated events, a distinction that is important to assess given the distinct clinical behavior and prognosis in clonally related vs unrelated cases, especially in the context of Richter's syndrome.
Among large B-cell lymphomas, those that develop as localized disease in association with thrombi, myxoma, or prosthesis in the heart appear to run an indolent clinical course with the option for localized treatment (e.g., resection of thrombus and/or prosthesis); among lymphomatous proliferations associated with effusions, those with BPEL-like^fea-tures associated with fluid overload and unrelated to HHV8 infection may regress following fluid drainage and should be distinguished from the aggressive type of PEL lymphoma.
